$PMVP 0.52 Developing
- Date
- Aug 31, 2026
- Mentions
- 1
- Unique authors
- 1
- Sector
- biotech
- Stance
- neutral
- On card
- no
Sentiment history
bullish
neutral
mixed
bearish
line = signal
dashed = price
No sentiment history available for $PMVP yet.
Sentiment
neutral 1
Notable posts
-
neutral 6 eng
PMV PHARMACEUTICALS $PMVP REPORTS 46% ORR IN OVARIAN CANCER TRIAL Updated interim data from the PYNNACLE Phase 2 pivotal trial of rezatapopt monotherapy, per the company. - Objective response rate: 46% among 76 ovarian cancer patients - Median time to response: 1.3 months - Median duration of response: 10.0 months - Discontinuation rate due to adverse events: 5%
view on X →
Only one day of history so far — the signal arc fills in as the daily job runs.